Recombinant antibodies and their derivatives are increasingly being used as therapeutic agents. Clinical applications of antibodies often require large amounts of highly purified molecules, sometimes for multiple treatments. The development of very efficient expression systems is essential to the full exploitation of the antibody technology. Production of recombinant protein in the milk of transgenic dairy animals is currently being tested as an alternative to plasma fractionation for the Ž manufacture of a number of blood factors human antithrombin, human alpha-1-antitrypsin, human serum albumin, factor . IX . The ability to routinely yield mgrml levels of antibodies and the scale-up flexibility make transgenic production an attractive alternative to mammalian cell culture as a source of large quantities of biotherapeutics. The following review examines the potential of transgenic expression for the production of recombinant therapeutic antibodies. q 1999 Elsevier Science B.V. All rights reserved.
Introduction
One of the challenges created by the biotechnology revolution is the development of methods for the economical production of highly purified proteins at large scales. Recent developments indicate that expression of recombinant proteins in the milk of transgenic animals may be particularly well suited for the production of complex polypeptides.
Since Edward Jenner first used cowpox to protect against smallpox, the use of the immune system to ) Corresponding author.
fight disease has proven spectacularly successful.
Ž The arrival of the hybridoma technology Kohler and . Milstein, 1975 brought a new level of therapeutic potential to the use of the immune mechanisms, with monoclonal antibodies being widely recognized as potential ''magic bullets''. However, when monoclonal antibodies were found to be effective in vitro, Ž . their xenogenic murine nature led to the development human anti-mouse-antibody responses in pa-Ž . tients Borrebaeck et al., 1993; Khazaeli et al., 1994 , often precluding repeat treatments. Only, after the Ž development of approaches recently reviewed in . Vaughan et al., 1998 permitting the production of ( ) Ž . monoclonal antibodies that are or appear human, could the clinical benefits of these agents be fully realized.
The pace of approval of monoclonal antibodies for various conditions has recently accelerated: ab-Ž . ciximab Reoproe for the prevention of acute cardiac ischemia following coronary angioplasty, ritux-Ž . imab Rituxane for the treatment of non-Hodgkin Ž . B-cell lymphoma, trastuzumab Herceptine for Ž . metastatic breast cancer, infliximab Remicadee for Ž severe Crohn's disease and rheumatoid arthritis Hall, 1995; Glaser, 1996; Sherman-Gold, 1997; Dickman, . 1998; Hoyle, 1998; Webber, 1998 . Since therapeutic antibodies are often developed to treat clinical indications that have a large number of patients Ž . cancers, arthritis and that their effective dose is generally rather large, it has been imperative to develop very efficient recombinant protein production technologies.
Mammalian cell culture has emerged as the method of choice for the production of most monoclonal antibodies currently commercialized. However, even with improvements in culture technology and fermentation scale-up, costs of purified antibod-Ž ies in the range of 1000 to 2000 US$rg at 10,000
. liter fermentation scale are not uncommon with Ž higher costs for smaller fermentation scale Werner, . 1998 . Alternative systems are being developed, with the objective of lowering capital investments and cost of goods associated with large scale production of recombinant monoclonal antibodies. These in-Ž clude microbial and insect cell-based recently re-. Ž viewed in Verma et al., 1998 , plant-based reviewed . in Larrick et al., 1998 , as well as transgenic animal-based production systems. This review will focus on the production of recombinant monoclonal antibodies in the milk of transgenic animals, summarizing the status of the technology and examining potential advantages and challenges.
The mammary gland expression system
The ability to modify animal genomes through microinjection technology has offered new alternatives for the manufacture of recombinant proteins. Targeting the production of human recombinant protein pharmaceuticals to the milk of transgenic farm Ž animals recently reviewed by Houdebine, 1995; Maga and Murray, 1995; Echelard, 1996; Clark, . 1998; Meade et al., 1998 solves many of the problems associated with either microbial or animal cell expression systems. Bacteria often improperly fold complex proteins, introducing more involved and expensive processes, and both bacteria and yeast lack adequate post-translational modification. Bioreactors for cell cultures require high initial capital expenditures, use large volumes of expensive culture media, and often suffer from relatively low yields.
To express a recombinant protein in the milk of a Ž . transgenic animal Fig. 1 , expression vectors containing a gene encoding the protein of interest fused Ž . to milk specific regulatory elements Fig. 2 are generally introduced by microinjection of a one-cell embryo, or alternatively transfected into a cell line suitable for somatic cell nuclear transfer. Following integration into the germline, the mammary glandspecific transgene is transmitted in Mendelian fashion and, if expressed, becomes a dominant genetic characteristic that will be predictably inherited by offspring of the founder animal. Often, transgenic Ž . animals will express the protein s of interest in gram per liter quantities depending on the mammary-specific regulatory sequences employed, the gene to be expressed, as well as the integration site of the transgene.
Milk-specific transgenes
Transgenes targeting the expression of recombinant proteins to the mammary gland are usually chimeric, being derived from the fusion of the gene Ž . encoding the protein s of interest with mammary-Ž . specific regulatory sequences Fig. 2 . Regulatory sequences from several milk-specific genes have been isolated and used first in transgenic mice, then in large animals. Most of this work has been carried out Ž with: the ovine b-lactoglobulin gene, rodent mouse, . Ž . rat and rabbit whey acid protein WAP genes, bovine a-lactalbumin and a-s1-casein genes, as well Ž as the caprine b-casein gene reviewed in Maga and . Murray, 1995; Echelard, 1996; Meade et al., 1998 . According to the regulatory sequences employed, variable levels of expression for the protein of interest were observed. For example, using the human ( ) Fig. 1 . Schematic representation of the transgenic production process. The coding region of the protein to be expressed is linked to mammary gland specific regulatory elements. The resulting transgene is introduced by pronuclear microinjection into embryos of the Ž selected species alternatively, somatic cell nuclear transfer using cell lines transfected with the transgene can be used as method to create . Ž . transgenic sheeps, goats or cattle . Embryos are then transferred to the oviduct or the uterus of a surrogate mother and carried to term. Transgenic offspring are identified and, when mature, are either bred or hormonally induced to lactate. Expression level of the target protein in the milk of transgenic animals is determined and a suitable founder line is chosen for the generation of the production herd.
Ž
. tissue plasminogen activator tPA cDNA only low Ž . level mgrml expression was observed with transgenic rabbits and mice when using a construct containing 1.6 kb of bovine a-s1-casein 5 X -flanking se-Ž . quences Riego et al., 1993 , whereas the human tPA cDNA under the control of caprine b-casein se-quences was expressed at high levels in transgenic Ž . goat's milk ) 1 mgrml; Ebert et al., 1991 Ebert et al., , 1994 Recombinant protein expression will vary according to the nature and size of the mammary gland regula-Ž tory elements as well as the nature cDNA or ge-. nomic and sequence of the expressed gene. Usually ( ) genomic transgenes are expressed at higher levels Ž than cDNA transgenes Whitelaw et al., 1991; Hur-. witz et al., 1994 . However, systematic studies comparing side by side the expression of cDNA and genomic antibody transgenes in milk have not been published.
Species selection
Several animal species have been used for produc-Ž . tion of recombinant proteins in milk Table 1 . The choice of animal to employ for transgenic expression is determined by the amount of protein needed as well as reproductive characteristics. Transgenic mice represent an ideal system to test expression constructs prior or concomitant to the generation of larger founder transgenic animal. Fortunately, the milk promoter sequences from all mammals tested are capable of expression in the mouse mammary gland. This allows the relatively inexpensive and rapid testing and optimization of the transgene constructs. If expression of the transgene by the mammary gland is deleterious to the health of the animal, Ž it will be often evident in the mouse model Devinoy . et al., 1994; Korhonen et al., 1997 . However, the very limited murine milk yield restricts expression of recombinant proteins to milligram quantities.
Rabbits have been used for the production of Ž gram amounts of proteins Massoud et al., 1991; Brem et al., 1994; Korhonen et al., 1997; Stromqvist . et al., 1997; Coulibaly et al., 1999 . However, their labor-intensive milking and high husbandry costs preclude using rabbits for the production of kilograms of therapeutic antibodies. To this end, dairy goats are ideal. The average milk output per doe is 600 to 800 liters per 300-day lactation, although yields greater than 1000 liters per lactation have been recorded. Recombinant antibody concentration in milk in the range between 1 and 5 grl has been reproducibly achieved by this group. In these conditions, herds of transgenic goats of manageable size could easily yield 1 to 300 kg of purified product per year. This represents the low to middle range of the high-volume protein category that would be required for the majority of therapeutic antibodies currently under development.
Moreover, the time from initiating microinjection Ž to full lactation gestationq growth to sexual matu-. rity q gestation is 16 to 18 months for goats. For cattle, it is approximately 3 years. Thus, the shorter caprine interval permits expansion of the production herds within the time frame needed for regulatory approval of the transgenically produced therapeutic proteins. Finally, there is a much lower incidence of Ž scrapie in goats only 7 cases reported by the United . States Department of Agriculture through 1998 rela-Ž tive to sheep 1117 US cases through 1992; Wineland . et al., 1998 which have an almost similar reproductive performance but lower lactation output.
Introduction of transgenes in the germline
To date, the method most frequently employed to produce transgenic animals has been pronuclear mi-Ž croinjection exhaustively reviewed, among others, . by Pinkert, 1994; Houdebine, 1996 . Techniques allowing the direct microinjection of foreign genes into murine pronuclei were adapted to gene transfer into the pronuclei of rabbits, pigs and ruminants ŽHammer et al., 1985; Bondioli et al., 1991; Ebert et . al., 1991 . Generally, fertilized eggs are flushed from the oviduct of superovulated donors, microinjected with a few hundred copies of the transgene, transferred to the uterus or oviduct of pseudopregnant Ž recipients following more or less extensive culture . in vitro , and developed to term. In cattle, one cell stage embryos generated from in vitro matured and in vitro fertilized slaughterhouse-derived oocytes can also be used.
While successful and widely used, the microinjection approach has had limited efficiency. Transgene integration into the genome of founder animals is Ž . low, varying from less than 0.1% cattle to 5% Ž . mice of the microinjected embryos producing transgenic offspring. Moreover, the frequent generation of founder animals carrying the transgene in Ž . only a subset of their cells mosaics following Ž pronuclear microinjection Wilkie et al., 1986; Bur-. don and Wall, 1992; Whitelaw et al., 1993 can complicate the expansion of transgenic herds by reducing the frequency of germline transmission of Ž . the transgene s .
The recent discovery that differentiated somatic cells can function as karyoplast donors for nuclear transfer has provided a wide range of possibilities for Ž germline modification in sheep Campbell et al., . Ž 1996; Wilmut et al., 1997 , cattle Cibelli et al., . Ž . 1998 and goat Baguisi et al., 1999 . The use of recombinant somatic cell lines for nuclear transfer allows the introduction of transgenes by traditional transfection methods. It has the potential to increase the efficiency of transgenic animal production and overcome the problem of founder mosaicism. However, transfected somatic cell nuclear transfer has not been used very extensively yet and its efficacy in the various ruminant species is undetermined.
In addition to successful transgenic founder production, somatic cell nuclear transfer could allow for the selection of the appropriate transgenic cell line before the generation of cloned transgenic embryos. This would be particularly important for the transgenic production of recombinant monoclonal antibodies in milk where heavy chain and light chain Ž . Fig. 3 . Fluorescence in situ hybridization FISH of blood metaphase spread form a transgenic goat carrying heavy and light chain antibody Ž . Ž . transgenes co integrated in the same chromosome A 150 = ; B 300 = . The heavy chain-specific signal is red, the light chain-specific signal is green.
( ) transgenes should be expressed in the same secretory cells of the mammary epithelium at equivalent levels. It is also important that transgenes expressing each protein are co-integrated in the same locus to avoid segregation of heavy chain and light chain Ž . transgenes during herd propagation Fig. 3 .
Expression of recombinant antibodies in milk
There are several reports of expression of antibod-Ž ies in the milk of transgenic animals summarized in . Ž . Table 2 . In one case Limonta et al., 1995 an Ž . anti-CD6 mouserhuman chimeric antibody IgG1 was expressed at levels up to 0.4 mgrml in the milk of mice carrying two transgenes respectively linking rabbit WAP regulatory sequences to genomic light chain and heavy chain sequences.
Ž . Even higher expression up to 5 mgrml was achieved in mice generated by co-microinjection of transgenes linking either ovine b-lactoglobulin Ž . Simons et al., 1987 or murine whey acid protein Ž . Shamay et al., 1991 regulatory sequences to cD-NAs encoding either chimeric mouserhuman or chimeric porcinerhuman light chain and heavy chain Ž anti-TGEV transmissible gastroenteritis coron-. Ž avirus IgG genes Castilla et al., 1998a,b; Sola et . Ž al., 1998 . Interestingly, similar expression levels up . to 6 mgrml were observed with the expression of the same anti-TGEV variable region linked to an IgA Ž . isotype Castilla et al., 1998a,b . In both cases, milk produced antibodies were found to be functional in a coronavirus neutralization assay.
In another example, two versions of angiogenin fused to E6, an antibody directed against the human Ž . transferrin receptor Hoogenboom et al., 1990 were expressed in transgenic mouse milk. The human Ž rmouse chimeric IgG1 version Newton et al., this . issue was expressed up to 0.8 mgrml. The single-Ž chain version Newton et al., submitted; Susanna . Rybak, personal communication was expressed up to 1.6 mgrml. The single-chain version was expressed in milk at levels 3000-fold greater than when produced in Escherichia coli, and was superior in Ž functional assays stability, antigen binding, protein . synthesis inhibition, cytotoxicity to the material purified from inclusion bodies. The IgG1 version was produced at levels ; 160,000-fold higher than was produced in a myeloma cell culture system, and Ž retained all biological properties Newton et al., this issue; submitted; Susanna Rybak, personal communi-. cation . These data illustrate the potential of the mammary gland expression system for the production of immunoglobulin-enzyme fusion proteins. Fig. 4 . SDS-PAGE and Western analysis of several antibodies produced in mice and goats. Two 10-18% SDS-PAGE gels were Ž . electrophoresed in parallel under reducing conditions. A Lanes were loaded with 0.2 ml of either mouse or goat milk and stained with Ž . Ž . Coomassie Brilliant Blue R250 Sigma . B Lanes were loaded with 0.1 ml of either mouse or goat milk. Antibodies were detected with Ž . Ž . affinity purified HRP-goat anti-human IgG Cappel and an Enhanced Chemiluminescence Kit Amersham . This antibody recognizes the Ž . heavy chain more efficiently than the light chain. Lane 1. 10 mgrml of standard antibody in water . Lane 2. Pre-stained molecular weight Ž . markers Biorad low-range, lot 77813 . Lane 3. Negative mouse milk. Lane 4. Negative mouse milk spiked with 10 mgrml of antibody standard. Lane 5. hBR96-2 a humanized IgG1 produced in mouse milk. Lane 6. Human IgG1 produced in mouse milk. Lane 7. Humanized IgG4 produced in mouse milk. Lane 8. Negative goat milk. Lane 9. Negative goat milk spiked with 10 mgrml of standard antibody. Lane 10. hBR96-2 a humanized IgG1 produced in goat milk. Lane 11. Human IgG1 produced in goat milk, hormonally induced lactation. Lane 12. Human IgG1 produced in goat milk, natural lactation.
In our group, transgenic mice and goats have been generated for the expression of seven different mon-Ž oclonal antibodies Gavin et al., 1997; Pollock et al., . unpublished . High-level expression in transgenic mice was observed in all cases. In projects where goat expression data is already available, levels of recombinant antibodies were equivalent or higher to that observed in the corresponding transgenic mouse Ž models see characteristic examples in Figs. 4 and . 5 . All the expression constructs for these studies employed the caprine b-casein regulatory elements Ž . DiTullio et al., 1992; Roberts et al., 1992 linked to either genomic or cDNA genes coding for the heavy and light chain sequences.
In one example, hBR96-2, a humanized IgG1 version of the BR96 anti-LewisY monoclonal antibody developed at Bristol Myers Squibb for anti-Ž cancer applications Rosok et al., 1996; Tolcher et . al., 1999 was expressed in mice and goats. Transgenic animals were generated by co-microinjection Ž . of the milk expression constructs Fig. 2 . Twenty double transgenic mouse lines were generated, carrying both the heavy and light chain transgenes. Anti- Fig. 5 . Milk and antibody production during the first natural lactation of a transgenic goat.
( ) body expression up to 4 mgrml was detected in transgenic mouse milk. A total of five transgenic goat lines was also generated by co-microinjection Ž . Gavin et al., 1997 , three of which carried both Ž . transgenes one male and two female founders . Expression up to 14 grl has been recorded in the milk of one of the female founders. High-level ex-Ž . pression 5 grl was also observed from female offspring of the male founder. The other female Ž . founder only produced low-levels 0.1 grl of the Ž . antibody D. Pollock et al., in preparation . It was also shown that the milk produced hBR96-2 antibody has retained full antigen binding properties Ž . Perry Fell, personal communication .
Purification of recombinant human antibodies produced in goat milk
The published literature contains a wealth of information concerning the purification of monoclonal Ž antibodies Prior, 1991; Ransohoff and Levine, 1991; Brooks et al., 1992; Graf et al., 1994; Page and . Thorpe, 1998 . The challenge of monoclonal antibody purification from cell culture is that high volumes of the conditioned culture media needs to be processed due Ž . to lower expression level usually in the mgrl range . Typical contaminants in serum free media are cell debris, lipids, host DNA, host cell proteins, viruses Monoclonal antibodies produced in the milk of transgenic goats at the relatively modest level of 2 grl represent 7% of the total protein. As the antibody is expressed as a whey protein, standard dairy procedures can be adapted to the initial separation step to achieve a casein-free, fat-free and lactose-free protein concentrate in which the antibody is at 30-60% purity, depending on the expression level. Fat may be separated from milk using standard centrifugal procedures or by membrane filtration. Membrane filtration can be used to eliminate most of the caseins and small molecules. The clarified whey is excellent starting material for chromatographic purification. Alternatively, either whole milk or the whey fraction can be subject to direct capture using expanded or fluidized bed techniques.
The purification of a recombinant human or humanized antibody from milk involves the separation of endogenous whey proteins from the antibody. The techniques employed vary with the type and class of antibody expressed. They include ion exchange chromatography, hydrophobic interaction chromatogra-Ž phy and affinity chromatography Protein A or Pro-. tein G . Affinity supports from different manufacturers vary and conditions may be found that do separate IgGs of different species. Goat milk contains 0.3-0.5 grl of endogenous caprine Ig which can be separated from the recombinant human or humanized Ž IgG. In our hands Joseph Kutzko et al., unpub-. lished using a combination of chromatographic steps, human IgG was successfully purified from the clari-Ž . fied milk of a transgenic goat Fig. 6 . A ) 3 Log 10 reduction of goat IgG is achieved in a single step at a theoretical purity of 99.9% with a yield of 65% for the unoptimized process.
Conclusion
It is possible to achieve high-level expression of active recombinant immunoglobulins and immunoglobulin-fusions in the milk of transgenic animals. Transgenic expression delivers the advantages of mammalian cells such as a sophisticated refolding machinery and glycosylation. Other features of trans-genic productions are scale-up flexibility since herd Ž . size can be increased or decreased rapidly and inexpensively, as well as the relative low-cost and low complexity of the raw product manufacturing Ž . facilities farms as compared to more traditional GMP cell culture facilities.
Further work is underway to fully evaluate the applicability of transgenically produced antibodies to therapeutic needs, in particular, studies of the functionality and pharmacokinetics of the milk-derived recombinant antibodies. It is expected that glycosylation structure of caprine mammary gland-derived antibodies will not be identical to CHO cell-derived material. However, there is very little evidence suggesting that differences in glycosylation resulting from expression in different mammalian host cells significantly influence the behavior of recombinant Ž . antibodies Bebbington, 1995 . In all cases, where it was examined, antigen binding of milk-expressed antibodies was found to be similar to equivalent mammalian cell culture derived molecules.
